4D Molecular Therapeutics, Inc.
FDMT
$11.21
$0.514.77%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2,900.00% | 200.00% | -50.00% | 105.26% | -99.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,900.00% | 200.00% | -50.00% | 105.26% | -99.99% |
| Cost of Revenue | 22.75% | 50.51% | 46.03% | 65.54% | 53.53% |
| Gross Profit | -22.52% | -50.48% | -46.13% | -65.42% | -691.46% |
| SG&A Expenses | -6.43% | 8.67% | 25.67% | 22.88% | 38.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.53% | 40.06% | 40.54% | 53.19% | 49.61% |
| Operating Income | -15.36% | -40.04% | -40.60% | -53.11% | -265.91% |
| Income Before Tax | -29.73% | -56.38% | -48.06% | -53.86% | -327.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.73% | -56.38% | -48.06% | -53.86% | -327.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.73% | -56.38% | -48.06% | -53.86% | -327.49% |
| EBIT | -15.36% | -40.04% | -40.60% | -53.11% | -265.91% |
| EBITDA | -15.58% | -41.27% | -42.22% | -54.77% | -284.76% |
| EPS Basic | -28.41% | -54.56% | -30.87% | -18.54% | -225.18% |
| Normalized Basic EPS | -23.44% | -54.55% | -30.88% | -18.53% | -225.12% |
| EPS Diluted | -28.41% | -54.56% | -30.87% | -18.54% | -225.18% |
| Normalized Diluted EPS | -23.44% | -54.55% | -30.88% | -18.53% | -225.12% |
| Average Basic Shares Outstanding | 1.03% | 1.17% | 13.14% | 29.80% | 31.47% |
| Average Diluted Shares Outstanding | 1.03% | 1.17% | 13.14% | 29.80% | 31.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |